Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




AI Model Accurately Identifies Prediabetics Using Only ECG Data

By HospiMedica International staff writers
Posted on 28 Jan 2026

Prediabetes is a silent metabolic condition that often goes undetected because it causes no obvious symptoms and typically requires blood tests for diagnosis. More...

Low participation in routine health checkups and the cost and invasiveness of laboratory testing further limit early detection. Yet this stage represents a critical window when lifestyle changes can prevent progression to type 2 diabetes. Researchers have now shown that subtle patterns in heart electrical activity can be used to identify people with prediabetes accurately, using only ECG data.

Researchers at the Institute of Science Tokyo (Tokyo, Japan), in collaboration with academic partners, have developed an artificial intelligence (AI) model called DiaCardia designed to detect prediabetes using either standard 12-lead ECGs or simplified single-lead ECG recordings. The goal was to create a noninvasive, scalable screening tool that could eventually work with consumer wearable devices.

DiaCardia is built on the LightGBM machine learning framework and analyzes waveform-level ECG features without relying on demographic inputs such as age or sex. The model extracts hundreds of quantitative features from ECG signals that reflect cardiac structure and autonomic regulation, both of which are known to be affected early in metabolic disease.

To train and evaluate the model, the researchers analyzed 16,766 health checkup records from a Tokyo clinic, each including fasting glucose, HbA1c values, and 12-lead ECG data. Prediabetes or diabetes was defined using standard clinical thresholds or ongoing diabetes treatment. In internal testing, DiaCardia achieved an AUROC of 0.851 using ECG data alone.

The findings, published in Cardiovascular Diabetology, show that the model also performed well in an external validation cohort from another institution without retraining, demonstrating strong generalizability. Explainable AI analysis showed that higher R-wave amplitudes and reduced heart rate variability were key predictors, aligning with known physiological effects of insulin resistance and autonomic dysfunction.

Notably, DiaCardia retained nearly the same predictive accuracy when applied to single-lead ECG data using far fewer features. This suggests the model could be deployed through wrist-worn wearables or home ECG devices, enabling large-scale, low-cost screening. Such an approach could significantly expand access to early prediabetes detection beyond clinical settings.

The researchers plan to further validate the model in broader populations and explore real-world integration with consumer ECG platforms. If confirmed, the technology could support continuous, noninvasive monitoring and earlier preventive interventions.

“This is the first robust, interpretable, and generalizable AI model capable of identifying individuals with prediabetes using either 12-lead or single-lead ECG data,” said Junior Associate Professor Chikara Komiya, who led the research team. “DiaCardia has the potential to make prediabetes screening scalable, accessible, and available anytime, anywhere, without a blood test. By promoting widespread screening of prediabetes, this work will ultimately contribute to the prevention of diabetes.”

Related Links:
Institute of Science Tokyo


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.